Abstract
Retraction: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have